Zhongguancun (000931.SZ): Application for marketing licensing of oxycodone hydrochloride sustained-release tablets (specification: 40mg) accepted

Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. The company's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter: Beijing Huasu), recently received the “Notice of Acceptance” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration), and the marketing license application for oxycodone hydrochloride sustained-release tablets (specification: 40mg) was accepted.

According to reports, oxycodone hydrochloride extended-release tablets are clinically used to treat pain that is severe enough to be continued for a long period of time, treated with opioids on time every day, and that cannot be adequately relieved by alternative treatment. Oxycodone hydrochloride is a pure opioid receptor agonist. It is relatively selective for μ-receptors and can also bind to other opioid receptors at higher doses; the main therapeutic effect of oxycodone is analgesia. The original research drug of this product was approved for marketing in China in 2021. Currently, 2 generic drugs have been approved for listing in China, and 1 domestic company has submitted a marketing license application. Beijing Huasu is the fourth domestic company to submit a marketing license application for this generic drug. As of the disclosure date of this announcement, the oxycodone hydrochloride sustained-release tablet project has invested a total of 13.911,800 yuan in R&D expenses.